CL2015001241A1 - Uso de interleucina 2 (il-2) para tratar trastornos inflamatorios o relacionados con la autoinmunidad (div. sol. n° 2608-13) - Google Patents

Uso de interleucina 2 (il-2) para tratar trastornos inflamatorios o relacionados con la autoinmunidad (div. sol. n° 2608-13)

Info

Publication number
CL2015001241A1
CL2015001241A1 CL2015001241A CL2015001241A CL2015001241A1 CL 2015001241 A1 CL2015001241 A1 CL 2015001241A1 CL 2015001241 A CL2015001241 A CL 2015001241A CL 2015001241 A CL2015001241 A CL 2015001241A CL 2015001241 A1 CL2015001241 A1 CL 2015001241A1
Authority
CL
Chile
Prior art keywords
autoimmune
div
interleukin
sol
related disorders
Prior art date
Application number
CL2015001241A
Other languages
English (en)
Inventor
David Klatzmann
David Saadoun
Patrice Cacoub
Michèle Rosenzwajg
Eliane Piaggio
Gilbert Bensimon
Claude Bernard
Original Assignee
Assistance Publique Hôpitaux De Paris
Univ Pierre Et Marie Curie Paris 6
Inserm Inst Nat De La Santé Et De La Rech Médicale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57232567&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015001241(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Assistance Publique Hôpitaux De Paris, Univ Pierre Et Marie Curie Paris 6, Inserm Inst Nat De La Santé Et De La Rech Médicale filed Critical Assistance Publique Hôpitaux De Paris
Publication of CL2015001241A1 publication Critical patent/CL2015001241A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

La presente invención se refiere tratamientos novedosos basados en IL-2 para tratar enfermedades autoinmunes e inflamatorias. De forma más específica, la presente invención se refiere al uso de una dosis baja de IL-2 para el tratamiento de la diabetes de tipo I y otras enfermedades autoinmunes y/o inflamatorias.
CL2015001241A 2011-03-11 2015-05-08 Uso de interleucina 2 (il-2) para tratar trastornos inflamatorios o relacionados con la autoinmunidad (div. sol. n° 2608-13) CL2015001241A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161451663P 2011-03-11 2011-03-11
EP11305269 2011-03-11

Publications (1)

Publication Number Publication Date
CL2015001241A1 true CL2015001241A1 (es) 2015-08-14

Family

ID=57232567

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2013002608A CL2013002608A1 (es) 2011-03-11 2013-09-10 Uso de dosis bajas de il -2 para tratar transtornos inflamatorios y relacionados con la autoinmunidad
CL2015001241A CL2015001241A1 (es) 2011-03-11 2015-05-08 Uso de interleucina 2 (il-2) para tratar trastornos inflamatorios o relacionados con la autoinmunidad (div. sol. n° 2608-13)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2013002608A CL2013002608A1 (es) 2011-03-11 2013-09-10 Uso de dosis bajas de il -2 para tratar transtornos inflamatorios y relacionados con la autoinmunidad

Country Status (5)

Country Link
US (4) US9669071B2 (es)
JP (3) JP6416855B2 (es)
BR (1) BR112013023151A2 (es)
CL (2) CL2013002608A1 (es)
ES (1) ES2811624T3 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2811624T3 (es) 2011-03-11 2021-03-12 Hopitaux Paris Assist Publique Régimen de dosificación de IL-2 para tratar lupus eritematoso sistémico
HUE039577T2 (hu) 2011-06-01 2019-01-28 Intrexon Actobiotics Nv Policisztronos expressziós rendszer baktériumokhoz
WO2015162124A1 (en) * 2014-04-22 2015-10-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnostic of an autoimmune disease
SG11201700629TA (en) 2014-08-11 2017-02-27 Delinia Inc Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases
GB201515244D0 (en) * 2015-08-27 2015-10-14 Univ Birmingham Treatment of inflammatory disease or condition
EP3402499B1 (en) 2016-01-14 2021-07-21 Intrexon Actobiotics NV Compositions and methods for the treatment of type 1 diabetes
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
US11077172B2 (en) 2016-11-08 2021-08-03 Delinia, Inc. IL-2 variants for the treatment of psoriasis
CA3056630A1 (en) 2017-03-15 2018-09-20 Pandion Therapeutics, Inc. Targeted immunotolerance
CA3064435A1 (en) 2017-05-24 2018-11-29 Pandion Therapeutics, Inc. Targeted immunotolerance
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
EP3927368A4 (en) 2019-02-20 2022-10-19 KSL Biomedical Inc. METHODS FOR PREDICTING AND MONITORING THE EFFECTIVENESS OF LOW-DOSE IL-2 AND HYDROXYCHLOROQUINE THERAPY IN AUTOIMMUNE DISEASES AND ITS LONG-TERM USE IN AUTOIMMUNE-RELATED DISORDERS
CN109999179A (zh) * 2019-05-08 2019-07-12 山东省分析测试中心 低剂量白介素2用于制备治疗阿尔茨海默病药物中的应用
BR112021023345A2 (pt) 2019-05-20 2022-02-01 Pandion Operations Inc Imunotolerância com alvo em madcam
US20210059962A1 (en) * 2019-09-03 2021-03-04 Regen BioPharma, Inc. Stimulation of t regulatory cells by cannabidiol as a means of treating arthritis and autoimmunity
WO2021127557A1 (en) * 2019-12-18 2021-06-24 Washington University Compositions and methods for treatment of headache disorders and neuropathic pain
KR102653906B1 (ko) 2020-01-14 2024-04-03 신테카인, 인크. 편향된 il2 뮤테인 방법 및 조성물
WO2022031884A2 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Il2rg binding molecules and methods of use
WO2022150788A2 (en) 2021-01-11 2022-07-14 Synthekine, Inc. Compositions and methods related to receptor pairing
WO2024043975A1 (en) * 2022-08-25 2024-02-29 Board Of Regents Of The University Of Nebraska Induction and expansion of regulatory t cells

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63183538A (ja) * 1986-09-01 1988-07-28 Takeda Chem Ind Ltd 関節リウマチまたは全身性エリテマト−デスの改善，治療剤
EP0262802A3 (en) 1986-09-01 1990-01-31 Takeda Chemical Industries, Ltd. Medicament for the treatment or improvement of rheumatoid arthritis or systemic lupus erythematosus
US5466447A (en) 1988-06-29 1995-11-14 Amgen Inc. Method for treating psoriasis
AU7578091A (en) 1990-03-19 1991-10-21 Brigham And Women's Hospital Treatment of cachexia with interleukin 2
US5466477A (en) 1993-11-08 1995-11-14 Hawkins Chemical, Inc. Preparation of process cheese using liquid sodium phosphate
FR2769505B1 (fr) 1997-10-10 2000-06-30 Michael Gerard Tovey Compositions de cytokines a administrer a la muqueuse buccale, et leurs utilisations
GB9724838D0 (en) 1997-11-26 1998-01-21 Franks Christopher R Compositions
AU2002258606A1 (en) 2001-03-30 2002-10-15 Mayo Foundation For Medical Education And Research Aerosol administration of interleukin-2 liposomes
ATE441420T1 (de) * 2002-12-02 2009-09-15 Innate Pharma Interleukin-2 und gamma delta t zellaktivator enthaltende zusammensetzungen und deren verwendungen
WO2005007121A2 (en) 2003-07-18 2005-01-27 Massachusetts Institute Of Technology Mutant interleukin-2(il-2) polypeptides
US20070098685A1 (en) * 2005-01-19 2007-05-03 Brand Stephen J Methods and kits to treat chronic inflammatory immune diseases by administering a proteasome inhibitor and an interleukin 2 receptor agonist
CA2595959A1 (en) * 2005-01-27 2006-08-03 Novartis Vaccines And Diagnostics, Inc. Methods for treating renal cell carcinoma
RU2540018C2 (ru) 2008-03-13 2015-01-27 Биотест Аг Средство для лечения заболевания
DE102008023820A1 (de) 2008-05-08 2009-11-12 Aicuris Gmbh & Co. Kg Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
WO2010049438A2 (en) 2008-10-30 2010-05-06 Innate Pharma Improved methods of using phosphoantigens for the treatment of diseases
CA2749539C (en) 2009-01-21 2022-07-19 Amgen Inc. Compositions and methods comprising interleukin-2 mutants for treating inflammatory and autoimmune diseases
CN102462837B (zh) 2010-11-19 2016-08-03 生物林格斯Ip有限公司 抗炎组合物
ES2811624T3 (es) 2011-03-11 2021-03-12 Hopitaux Paris Assist Publique Régimen de dosificación de IL-2 para tratar lupus eritematoso sistémico

Also Published As

Publication number Publication date
US10765723B2 (en) 2020-09-08
US11559566B2 (en) 2023-01-24
US9669071B2 (en) 2017-06-06
JP6416855B2 (ja) 2018-10-31
CL2013002608A1 (es) 2014-05-30
ES2811624T3 (es) 2021-03-12
JP2019014743A (ja) 2019-01-31
JP2021006591A (ja) 2021-01-21
US20170304402A1 (en) 2017-10-26
US20190351023A1 (en) 2019-11-21
US10293028B2 (en) 2019-05-21
JP2017061551A (ja) 2017-03-30
US20210038691A1 (en) 2021-02-11
BR112013023151A2 (pt) 2020-09-15
US20140004080A1 (en) 2014-01-02

Similar Documents

Publication Publication Date Title
CL2015001241A1 (es) Uso de interleucina 2 (il-2) para tratar trastornos inflamatorios o relacionados con la autoinmunidad (div. sol. n° 2608-13)
CY1121203T1 (el) Θεραπευτικες χρησεις της εμπαγλιφλοζινης
MX347324B (es) Uso de dosis bajas de il-2 para tratar trastornos inflamatorios o relacionados con la autoinmunidad.
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
EA201490748A1 (ru) Лечение рассеянного склероза комбинацией лахинимода и финголимода
UY34859A (es) Análogos peptídicos de la exendina 4.
BR112013029256A2 (pt) "combinações farmacêuticas para uso no tratamento de pacientes com diabetes tipo 2, método de tratamento, e usos de lixisenatida e metformina".
BR112015027282A2 (pt) fenfluramina para uso no tratamento de síndrome de dravet
GT201400089A (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
GT201300215A (es) Inhibidores de glucosilceramida sintasa
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
AR092177A1 (es) Metodos para tratar o prevenir asma administrando un antagonista de il-4r
BR112013028666A2 (pt) compostos de pirazolo sulfonamida tricícilos e métodos para fazer e usar o mesmo
CR20130377A (es) Métodos y productos de fármaco para tratar enfermedad de alzheimer
AR101740A1 (es) Terapia de combinación y composiciones
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
CY1123490T1 (el) Συνθεσεις που προερχονται απο χιτοζανη
AU2014265671A8 (en) Substituted bridged urea analogs as sirtuin modulators
GT201500168A (es) Polipéptidos estabilizados del factor de crecimiento tipo insulina
CO6592101A2 (es) Metodos para tratar ulceras de pie de diabetico
CL2016001578A1 (es) Piperidiniltetrahidroquinolinas sustituidas y su uso como antagonistas de los adenoreceptores alpha-2c.
DOP2017000123A (es) Análogos de urea unidos sustituidos como moduladores de sirtuina
BR112014030534A2 (pt) composições de galacto-ramnogalacturonato para o tratamento de doenças associadas com óxido nítrico sintase induzível elevada
EA201690191A1 (ru) Фармацевтическая композиция для замедленного высвобождения ланреотида
UY35328A (es) Tratamiento de formas progresivas de esclerosis múltiple con laquinimod